The Experts below are selected from a list of 8685 Experts worldwide ranked by ideXlab platform
Antonio Leccisotti - One of the best experts on this subject based on the ideXlab platform.
-
Prognosis of orbital Lymphoid Hyperplasia
Graefe's Archive for Clinical and Experimental Ophthalmology, 1996Co-Authors: Ennio Polito, Antonio LeccisottiAbstract:• Background Orbital Lymphoid Hyperplasia can be associated with systemic non-Hodgkin lymphoma (NHL), even when polyclonal proliferation is found in the orbit. Although irradiation is recommended, some orbital Lymphoid Hyperplasias are treated by steroids (when inflammation is clinically presumed) or left untreated. • Methods The incidence of concurrent NHL and the incidence of future NHL after oral prednisone, radiotherapy, or no treatment were retrospectively evaluated in 33 cases of Lymphoid Hyperplasia (22 benign Lymphoid Hyperplasias, BLH, and 11 atypical Lymphoid Hyperplasias, ALH), after follow-up of 2–13 years. • Results NHL occurred in 12 of 33 cases (36.4%). In seven patients it was concurrent; in five patients it occurred 2–6 years later. In the actuarial curve, at 5 years 55% of patients were free of lymphoma, at 10 years, 46%. NHL was more commonly observed when the lacrimal gland was involved (57% vs 21%; P =0.03). Of the 13 patients treated with oral steroids, 46% had complete response, 39% partial response, and 15% future NHL. Of the seven irradiated patients, five (71%) had complete response, two (29%) partial response, and none future NHL. Of the eight untreated patients, five (63%) had partial response and three (37%) future NHL. Irradiated lacrimal gland BLHs only achieved partial response, one having radiation-induced orbital inflammation. • Conclusion Because of a high risk of NHL, in all orbital Lymphoid tumors systemic staging and follow-up are mandatory. The advised management is irradiation, except for Sjögren syndrome, an initially inflammatory lacrimal gland BLH, where a course of steroid is suggested before considering radiotherapy.
-
Prognosis of orbital Lymphoid Hyperplasia.
Graefe's Archive for Clinical and Experimental Ophthalmology, 1996Co-Authors: Ennio Polito, Antonio LeccisottiAbstract:• Background Orbital Lymphoid Hyperplasia can be associated with systemic non-Hodgkin lymphoma (NHL), even when polyclonal proliferation is found in the orbit. Although irradiation is recommended, some orbital Lymphoid Hyperplasias are treated by steroids (when inflammation is clinically presumed) or left untreated.
Chincheng Lee - One of the best experts on this subject based on the ideXlab platform.
-
ectopic and high cxcl13 chemokine expression in myasthenia gravis with thymic Lymphoid Hyperplasia
Journal of Neuroimmunology, 2010Co-Authors: Yuming Shiao, Chincheng Lee, Yunghsiang Hsu, Shiufeng Huang, Chungyen Lin, Cathy S J Fann, Changyouh TsaiAbstract:Myasthenia gravis (MG) is an antibody and complement mediated autoimmune disease. Serum CXC chemokine ligand 13 (CXCL13) was found to be elevated in MG patients and high CXCL13 level was associated with severe clinical stages, especially in females with thymic Lymphoid Hyperplasia. Both protein and mRNA of CXCL13 and CXC chemokine receptor 5 (CXCR5) in the thymic tissues were significantly higher in MG patients with Lymphoid Hyperplasia than those with thymoma. Our data indicated that serum CXCL13 can be used as an index of disease severity and ectopic thymic expression of CXCL13 might be associated with aberrant cell trafficking to the thymus of MG.
Yuming Shiao - One of the best experts on this subject based on the ideXlab platform.
-
ectopic and high cxcl13 chemokine expression in myasthenia gravis with thymic Lymphoid Hyperplasia
Journal of Neuroimmunology, 2010Co-Authors: Yuming Shiao, Chincheng Lee, Yunghsiang Hsu, Shiufeng Huang, Chungyen Lin, Cathy S J Fann, Changyouh TsaiAbstract:Myasthenia gravis (MG) is an antibody and complement mediated autoimmune disease. Serum CXC chemokine ligand 13 (CXCL13) was found to be elevated in MG patients and high CXCL13 level was associated with severe clinical stages, especially in females with thymic Lymphoid Hyperplasia. Both protein and mRNA of CXCL13 and CXC chemokine receptor 5 (CXCR5) in the thymic tissues were significantly higher in MG patients with Lymphoid Hyperplasia than those with thymoma. Our data indicated that serum CXCL13 can be used as an index of disease severity and ectopic thymic expression of CXCL13 might be associated with aberrant cell trafficking to the thymus of MG.
Changyouh Tsai - One of the best experts on this subject based on the ideXlab platform.
-
ectopic and high cxcl13 chemokine expression in myasthenia gravis with thymic Lymphoid Hyperplasia
Journal of Neuroimmunology, 2010Co-Authors: Yuming Shiao, Chincheng Lee, Yunghsiang Hsu, Shiufeng Huang, Chungyen Lin, Cathy S J Fann, Changyouh TsaiAbstract:Myasthenia gravis (MG) is an antibody and complement mediated autoimmune disease. Serum CXC chemokine ligand 13 (CXCL13) was found to be elevated in MG patients and high CXCL13 level was associated with severe clinical stages, especially in females with thymic Lymphoid Hyperplasia. Both protein and mRNA of CXCL13 and CXC chemokine receptor 5 (CXCR5) in the thymic tissues were significantly higher in MG patients with Lymphoid Hyperplasia than those with thymoma. Our data indicated that serum CXCL13 can be used as an index of disease severity and ectopic thymic expression of CXCL13 might be associated with aberrant cell trafficking to the thymus of MG.
Ennio Polito - One of the best experts on this subject based on the ideXlab platform.
-
Prognosis of orbital Lymphoid Hyperplasia
Graefe's Archive for Clinical and Experimental Ophthalmology, 1996Co-Authors: Ennio Polito, Antonio LeccisottiAbstract:• Background Orbital Lymphoid Hyperplasia can be associated with systemic non-Hodgkin lymphoma (NHL), even when polyclonal proliferation is found in the orbit. Although irradiation is recommended, some orbital Lymphoid Hyperplasias are treated by steroids (when inflammation is clinically presumed) or left untreated. • Methods The incidence of concurrent NHL and the incidence of future NHL after oral prednisone, radiotherapy, or no treatment were retrospectively evaluated in 33 cases of Lymphoid Hyperplasia (22 benign Lymphoid Hyperplasias, BLH, and 11 atypical Lymphoid Hyperplasias, ALH), after follow-up of 2–13 years. • Results NHL occurred in 12 of 33 cases (36.4%). In seven patients it was concurrent; in five patients it occurred 2–6 years later. In the actuarial curve, at 5 years 55% of patients were free of lymphoma, at 10 years, 46%. NHL was more commonly observed when the lacrimal gland was involved (57% vs 21%; P =0.03). Of the 13 patients treated with oral steroids, 46% had complete response, 39% partial response, and 15% future NHL. Of the seven irradiated patients, five (71%) had complete response, two (29%) partial response, and none future NHL. Of the eight untreated patients, five (63%) had partial response and three (37%) future NHL. Irradiated lacrimal gland BLHs only achieved partial response, one having radiation-induced orbital inflammation. • Conclusion Because of a high risk of NHL, in all orbital Lymphoid tumors systemic staging and follow-up are mandatory. The advised management is irradiation, except for Sjögren syndrome, an initially inflammatory lacrimal gland BLH, where a course of steroid is suggested before considering radiotherapy.
-
Prognosis of orbital Lymphoid Hyperplasia.
Graefe's Archive for Clinical and Experimental Ophthalmology, 1996Co-Authors: Ennio Polito, Antonio LeccisottiAbstract:• Background Orbital Lymphoid Hyperplasia can be associated with systemic non-Hodgkin lymphoma (NHL), even when polyclonal proliferation is found in the orbit. Although irradiation is recommended, some orbital Lymphoid Hyperplasias are treated by steroids (when inflammation is clinically presumed) or left untreated.
